Ralf-Holger Voss

670 total citations
12 papers, 520 citations indexed

About

Ralf-Holger Voss is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ralf-Holger Voss has authored 12 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Ralf-Holger Voss's work include CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and T-cell and B-cell Immunology (4 papers). Ralf-Holger Voss is often cited by papers focused on CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and T-cell and B-cell Immunology (4 papers). Ralf-Holger Voss collaborates with scholars based in Germany, Switzerland and United Kingdom. Ralf-Holger Voss's co-authors include Matthias Theobald, Jürgen Kuball, Philippe Guillaume, Pedro Romero, Beate Hauptrock, Ulrich Ermler, Lars‐Oliver Essen, Matthias Wölfl, Philip D. Greenberg and Roland K. Strong and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and The Journal of Immunology.

In The Last Decade

Ralf-Holger Voss

12 papers receiving 519 citations

Peers

Countries citing papers authored by Ralf-Holger Voss

Since Specialization

Citations

This map shows the geographic impact of Ralf-Holger Voss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf-Holger Voss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf-Holger Voss more than expected).

Fields of papers citing papers by Ralf-Holger Voss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf-Holger Voss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf-Holger Voss. The network helps show where Ralf-Holger Voss may publish in the future.

Co-authorship network of co-authors of Ralf-Holger Voss

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf-Holger Voss. A scholar is included among the top collaborators of Ralf-Holger Voss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf-Holger Voss. Ralf-Holger Voss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination 2022 ·Cancer Research Communications ·Matthias Birtel, Ralf-Holger Voss, Katharina Reinhard, Benjamin Rengstl, (unknown), Kristina Michel, (unknown), Bodo Tillmann, (unknown), M Suchan, Matthias Theobald, Petra Oehm, Özlem Türeci, Uğur Şahin	16
2	CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro 2021 ·Journal of Translational Medicine ·(unknown), Matthias Birtel, Elham Masoumi, Leila Jafarzadeh, (unknown), Jamshid Hadjati, Ralf-Holger Voss, Mustafa Diken, (unknown)	27
3	A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo 2018 ·Molecular Therapy ·Hakim Echchannaoui, Jutta Petschenka, Edite Antunes Ferreira, Beate Hauptrock, (unknown), Ralf-Holger Voss, Matthias Theobald	10
4	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells 2016 ·Oncotarget ·(unknown), Sebastian Klobuch, Shao‐An Xue, Matthias Birtel, Hakim Echchannaoui, (unknown), Tana Omokoko, Philippe Guillaume, Pedro Romero, Hans J. Stauss, Uğur Şahin, Wolfgang Herr, Matthias Theobald, Simone Thomas, Ralf-Holger Voss	29
5	Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by Arginine Depletion 2013 ·PLoS ONE ·Markus Munder, Mélanie Engelhardt, (unknown), (unknown), Guido Wabnitz, Claudia Luckner‐Minden, (unknown), Ralf-Holger Voss, Pascale Kropf, Ingrid Müller, Roland Conradi, Yvonne Samstag, Matthias Theobald, Anthony D. Ho, Hartmut Goldschmidt, Michael Hundemer	31
6	Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells 2010 ·Blood ·Ralf-Holger Voss, Simone Thomas, Christina Pfirschke, Beate Hauptrock, Sebastian Klobuch, Jürgen Kuball, (unknown), (unknown), Philippe Guillaume, Pedro Romero, Christoph Huber, Philipp Beckhove, Matthias Theobald	35
7	Increasing functional avidity of TCR-redirected T cells by removing defined N -glycosylation sites in the TCR constant domain 2009 ·The Journal of Experimental Medicine ·Jürgen Kuball, Beate Hauptrock, (unknown), (unknown), Ralf-Holger Voss, Matthias Wölfl, Roland K. Strong, Matthias Theobald, Philip D. Greenberg	111
8	Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice 2009 ·Haematologica ·(unknown), Lina Gao, Simone Thomas, Daniel P. Hart, John Z. Xue, Roopinder Gillmore, Ralf-Holger Voss, Emma Morris, H Stauss	50
9	Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells 2008 ·The Journal of Immunology ·Ralf-Holger Voss, Ralph A. Willemsen, Jürgen Kuball, (unknown), (unknown), (unknown), Philippe Guillaume, Pedro Romero, Christoph Huber, Matthias Theobald	70
10	Redirection of T Cells by Delivering a Transgenic Mouse-Derived MDM2 Tumor Antigen-Specific TCR and its Humanized Derviative Is Governed by the CD8 Coreceptor and Affects Natural Human TCR Expression 2006 ·Immunologic Research ·Ralf-Holger Voss, Jürgen Kuball, (unknown), Philippe Guillaume, Pedro Romero, Christoph Huber, Matthias Theobald	41
11	Designing TCR for Cancer Immunotherapy 2004 ·Humana Press eBooks ·Ralf-Holger Voss, Jürgen Kuball, Matthias Theobald	17
12	Crystal Structure of the Bifunctional Soybean Bowman‐Birk Inhibitor at 0.28‐nm Resolution 1996 ·European Journal of Biochemistry ·Ralf-Holger Voss, Ulrich Ermler, Lars‐Oliver Essen, (unknown), (unknown), (unknown)	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact